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Abstract
Survival statistics, estimated using data collected by national cystic ﬁbrosis (CF) patient registries, are used to inform the CF community andmonitor
survival of CF populations. Annual registry reports typically give the median age of survival, though different registries use different estimation
approaches and terminology, which has created confusion for the community. In this article we explain howmedian age of survival is estimated, what its
interpretation is, and what assumptions and limitations are involved. Information on survival from birth is less useful for individuals who have already
reached a certain age and we propose use of conditional survivor curves to address this. We provide recommendations for CF registries with the aim of
facilitating clear and consistent reporting of survival statistics. Our recommendations are illustrated using data from the UK Cystic Fibrosis Registry.
© 2017 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Annual report; Birth cohort; Conditional survival; Median survival; Patient registry; Period estimates; UK Cystic Fibrosis Registry
1. Rationale
Survival statistics, estimated using data collected by national
cystic fibrosis (CF) patient registries, are used inform the CF
community and monitor survival of CF populations. Annual reg-
istry reports typically give the median age of survival, though
different registries use different estimation approaches and termi-
nology. Recently there have been efforts to standardize method-
ology and reporting [1,2]. Nonetheless, there remain disparities in
how survival is explained [3–5] (Supplementary Table 1), creating
confusion for the community. Our aim is to provide clear descrip-
tions of survival statistics and recommendations for reporting.
2. Median age of survival
Here we explain how median age of survival estimates are
obtained, their interpretation, and the assumptions involved.
2.1. Survivor curves
A survivor curve shows the probability of living beyond
a specific age for a range of ages. The median survival age is
the age at which the survival probability is 0.5. Survivor curves
are estimated from a mathematical formula that uses the
proportion of individuals alive at each age who die before their
next birthday (the ‘age-specific mortality rate’), or an extension
of this which uses a finer time scale [6] (Supplementary
materials S1–S3). In addition to using information on deaths,
the calculations importantly also use the ages of people still
alive.
A survivor curve refers to the probabilities of living
beyond specific ages from birth. To know the survivor curves
for babies born today we would need to look into the future;
instead, we must use information available now. There are
two main ways of estimating curves: 1) the ‘period approach’
(a cross-sectional method) and 2) the ‘birth cohort approach’
(a longitudinal method). As illustrated in Fig. 1, these use
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different sets of individuals in the analysis, and are used to
answer different questions. The period approach provides the
most relevant information about predicted survival for babies
being born with CF today, while the birth cohort approach is
appropriate for comparing trends in survival in successive birth
cohorts.
2.2. The period approach
This approach [7,8], most often used by CF Registries,
estimates a survivor curve using mortality rates at each age for
people observed in the registry in a recent time period – usually
the most recent 5-year period (e.g. 1st January 2011–31st
December 2015). The mortality rate at each age is estimated
by the number of people alive at that age during the 5-year period
who died before their next birthday, divided by the total number
of people alive at that age during the 5-year period. Most
individuals advance through several ages during this period and
hence contribute to the estimated mortality rate at several ages.
Individuals do not contribute to estimated mortality rates for their
ages before the 5-year period. The 5-year period is used
to balance using data on a sufficient number of deaths for reliable
estimates of age-specific mortality rates, and obtaining estimates
that reflect current standards of care. The resulting estimated
median survival age has the following interpretation:
The estimated median survival age is the age beyond which
we expect 50% of babies with CF born today to live, under
the assumption that recent age-specific mortality rates will
hold for the rest of their lives.
Although period estimates of the survivor curve are
obtained using people born at different times, we emphasize
that the resulting survival statistics refer to a hypothetical
cohort of babies born in the present day with CF and subject
for the rest of their lives to current (2011–2015) age-specific
mortality rates. The resulting estimates are based on an
assumption that current mortality rates will apply in the future.
This may be reasonable at younger ages, but less reasonable at
older ages. For example, it assumes that the current mortality
rate at age 30 will still apply 30 years from now, when babies
born today would reach age 30. The estimates therefore do not
account for potential impacts of future improvements in
treatment.
Fig. 1. Illustrations contrasting the period approach and the birth cohort approach. Lines represent 12 individuals followed-up during 1st January 1985–31st
December 2015. Individuals 1 and 2 were born prior to 1985 and individuals 1, 4, 8 and 11 were known to be alive at the end of follow-up. Individual 7 was
lost-to-follow-up. Individuals 2 and 10 do not contribute to either analysis.
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2.3. The birth cohort approach
In this, survivor curves are estimated for a cohort of
individuals born in a specified time period, e.g. 1st January
1990 to 31st December 1995. The birth cohort approach is useful
for tracking the survival of successive cohorts of individuals with
CF [9,10]. However, estimates of survival from older cohorts
are out-of-date for babies born with CF today, and recent birth
cohorts cannot be used to estimate long term survival without
extrapolation because median survival can only be estimated
when 50% of the cohort have died [10].
3. Conditional survival
Information on survival from birth is less useful for individuals
who have already reached a certain age. We therefore propose use
of “conditional survivor curves” (Supplementary materials S4).
The conditional survivor curve (Fig. 3) from age 30 shows the
probability of survival beyond all ages greater than 30 for an
individual aged 30. The probability of living beyond age 35 for an
individual aged 30 is greater than the probability of living beyond
age 35 from birth.
Under the period approach, the conditional median survival
age has the following interpretation:
The estimated conditional median survival age from age A is
the age beyond which we expect 50% of individuals aged A
today to live, under the assumption that recent age-specific
mortality rates will hold for the rest of their lives.
4. Other survival statistics
‘Life expectancy’ is the mean (or ‘average’) age to which
individuals in a given population are expected to live from birth.
However, survival ages tend to have a skewed distribution and life
expectancy in CF can be strongly influenced by a few deaths at
older ages. Themean survival age therefore tends to be higher than
themedian survival age. Themedian is generally agreed to provide
a better summary statistic for survival ages. The median has the
further advantage that it corresponds clearly to a position on the
survivor curve and can be presented alongside other summary
statistics based on the survivor curve, as illustrated in Fig. 1.
CF registry reports also often present the ‘median age of
death’, which is obtained as the median of the ages at death of
all individuals who died in a given year (e.g. 2015). The median
age of death, as calculated in this way, does not consider the
population still alive and does not provide a summary of survival.
Unlike our recommended summary statistics of survival, this
median age of death depends on the current age-distribution of
the CF population. It is therefore not comparable across countries
or over time, because of differences in age-distributions.
5. Recommendations and illustration
Table 1 and Figs. 2 and 3 provide recommendations for
reporting and presentation of survival statistics in annual registry
reports, illustrated using data from the UK Cystic Fibrosis
Registry. Supplementary Fig. 1 shows conditional estimates for
males and females separately. All analyses are based on a period
approach using the Kaplan-Meier method [6], and coincide with
the analyses recommended by Sykes et al. [1]. For the period
approach we used data on individuals observed during 1st
January 2011–31st December 2015.
We recommend that estimates are accompanied by confidence
intervals [11,12], which provide information about the degree
of uncertainty in the estimates (Supplementary materials S5).
Estimates from small registries may be subject to year-to-year
fluctuations due to small numbers, and presentation of confidence
intervals helps to avoid over-interpretation.
Ideally, individuals should be followed-up for death post-
transplant in CF registries. Loss-to-follow-up due to transplant
may result in biased survival estimates and reports should be
clear on their handling of this [1,2].
Table 1
Recommendations for presentation of survival statistics in national CF registry
reports, illustrated using results from the UK Cystic Fibrosis Registry.
1. Present estimated survivor curves and the corresponding median survival
age showing 95% CIs, overall (Fig. 2a) and for males and females
separately (Fig. 2b), with the following text:
What is median age of survival?
The estimated median age of survival is an estimate of the age beyond
which we expect half of a population of individuals born today with CF in
the UK to live. The interpretation of the median survival age of 47 is
therefore that in a population of babies born today with CF half would be
expected to die before the age of 47 and half would be expected to live
beyond age 47.
Limitations
The estimation of the median age of survival assumes that age-specific
mortality rates in the future will be similar to those today. Although it
represents the best information available to us currently, it does not take into
account recent and future improvements in care and treatment that will impact
on survival. The median survival age refers to a population and not an
individual; it does not take into account individual features, such as genotype,
which impact on survival.
2. Present estimates of median age of survival conditional on survival to a
series of ages (Fig. 3), with the following text:
What is conditional median age of survival?
The estimated median age of survival conditional on survival to age A is the
age beyond which we expect 50% of individuals aged A in the present day to
live. For example, the median age of survival conditional on survival to age 30
is 55. Therefore we expect 50% of 30 year olds with CF today to live beyond
age 55.
Limitations
The limitations are similar to those for the overall median survival age.
Conditional estimates do not take into account an individual's current
health status, which is highly informative about their survival prospects.
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Fig. 2. Estimated survivor curves using data from the UK Cystic Fibrosis Registry. The shaded area shows the 95% confidence intervals and the down-arrow indicates the
estimatedmedian survival age. Estimates are based on the period approach using data on 10,946 individuals and 654 deaths observed in the 5-year period 1st January 2011–31st
December 2015.
Fig. 3. The upper plot shows estimates of median age of survival, conditional on survival to a given age. The dots show the estimated conditional median age of
survival from each age and the bars show the 95% CIs. Estimates are based on the period approach using data on individuals observed in the 5-year period 1st January
2011–31st December 2015. The lower plots show the estimated conditional survival curves from ages 30 and 40 indicating the conditional median age of survival.
Supplementary Fig. 1 shows estimates for males and females separately.
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6. Conclusions
Survival statistics are valuable outcomes for registry
reports. Standardized calculations and reporting aid interpretation
and facilitate inter-country comparisons. We have focused on
population-level survival. This does not incorporate individual
features affecting survival, such as genotype [13], socioeconomic
circumstances, or current health status, e.g. lung function. Further
analyses can provide estimates of survival based on individual
characteristics [14–16]. The methods we have described could in
theory be applied in individual centres. However, the estimates
would be expected to be subject to a large degree of uncertainty
due to small numbers. Comparisons between centres should be
made with caution, accounting for the features of the population
served by the centre as well as this uncertainty. We have
emphasized the limitation that survival estimates are based on an
assumption that current mortality rates will hold in the future.
There has been recent work to estimate trends in mortality rates in
the US and UK and to make projections of future survivor curves
based on different scenarios [13,17]. National registries may
consider providing such projections updated every 5 years or so.
Further work is needed to study the potential impacts of targeted
therapies on survival [18,19].
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